</Agent System Instructions>
<Blinded Review: TIME_ANON_0997>
**Composite Score:** 8.1 / 10.0 (Rigor: 2.7/3.5 | Claims: 2.0/2.5 | Biology: 1.6/2.0 | Reproducibility: 1.8/2.0)
**Bias Category:** Statistical/Design
**Verdict:** Minor Revision
**Study Modality:** Dry-Lab Secondary Cohort/Database
**Technology Maturity:** Mid-Stage High-Throughput
**Epistemic Stage:** Translational/Preclinical/Biomarker

OVERALL_SCORE: 8.1/10
VERDICT: PASS
ESTIMATED_DECADE: 2020s

---

### 1. Executive Summary / SUMMARY
This manuscript reports the first large-scale genome-wide association study (GWAS) meta-analysis specifically dissecting reticular pseudodrusen (RPD / subretinal drusenoid deposits) in age-related macular degeneration (AMD) across 14 international cohorts ($2,165\ \text{AMD}^+/\text{RPD}^+$, $4,181\ \text{AMD}^+/\text{RPD}^-$, and $7,639\ \text{AMD}^-/\text{RPD}^-$ controls; total $N = 13,985$). Comparing $\text{AMD}^+/\text{RPD}^+$ directly against $\text{AMD}^+/\text{RPD}^-$ (`GWAS1`), the authors demonstrate that the chromosome 10q26 *ARMS2/HTRA1/HTRA1-AS1* locus (`rs11200638`, $\beta = 0.26, P = 3.73 \times 10^{-15}$) is the sole genome-wide significant driver differentiating RPD+ from RPD- AMD, whereas the canonical chromosome 1q31 *CFH* locus is completely absent (despite 100% statistical power) because *CFH* increases risk equally for both RPD+ and RPD- AMD relative to healthy controls (`GWAS2` and `GWAS3`). The authors corroborate the chromosome 10 signal using AI-segmented OCT RPD macular extent ($N = 526$), 30x whole-genome sequencing of $N = 44$ extreme RPD cases ($\text{AMD}^+/\text{RPD}^{++}$), re-mapping of two post-mortem human retinal RNA-seq eQTL cohorts (NEI $N = 404$, Genentech $N = 119$) to quantify the newly annotated antisense lncRNA *HTRA1-AS1* (`ENSG00000285955`), and Bayesian colocalization (`coloc v5.2.2`) with UK Biobank OCT photoreceptor outer segment (OS) thickness ($\text{PPH4} = 0.99$) and parafoveal retinal thickness. While the core GWAS design, multi-cohort harmonization, and data/code sharing are exemplary, a forensic audit reveals a glaring numerical error in Table 1 and the main text where the reported odds ratio (`OR = 6.54`) lies completely outside its own reported 95% confidence interval (`CI = 11.4–33.76`), alongside a misinterpretation of dominant vs. recessive genetic model coefficients.

### 2. Methodological & Statistical Audit / STRENGTHS, WEAKNESSES & METHODOLOGICAL AUDIT

#### Strengths
- **Clean Within-Case Sub-Phenotype Design (`GWAS1` vs. `GWAS2`/`GWAS3`)**: Contrasting $\text{AMD}^+/\text{RPD}^+$ directly with $\text{AMD}^+/\text{RPD}^-$ ($N = 6,346$) while running parallel case-control comparisons against $N = 7,639$ $\text{AMD}^-/\text{RPD}^-$ controls cleanly separates pan-AMD complement susceptibility (*CFH* at 1q31) from RPD-specific subretinal pathology at 10q26 (*ARMS2/HTRA1/HTRA1-AS1*).
- **Comprehensive Robustness Checks**: The 10q26 association is invariant across leave-one-cohort-out meta-analyses (Supplementary Fig. 12b), AMD stage adjustments, exclusion of geographic atrophy (GA), exclusion of neovascular AMD (nAMD), and restriction to individual-level genotypes.
- **Annotation-Harmonized Retinal eQTL & Subcellular OCT Layer Colocalization**: Re-aligning both the NEI ($N = 404$) and Genentech ($N = 119$, 4 retinal/RPE regions) RNA-seq datasets to GRCh38.p14 (GENCODE v110) resolves why older eQTL studies missed *HTRA1-AS1*, and `coloc` specifically localizes the structural correlate to photoreceptor outer segment (OS) thinning ($\text{PPH4} = 0.99$) rather than inner segment ($\text{PPH4} = 0.58$) or outer nuclear layer ($\text{PPH4} = 0.26$) thickness.

#### Weaknesses & Methodological Audit
1. **Mathematical Contradiction in Table 1 and Main Text (`OR = 6.54` Outside Its Own 95% CI `11.4–33.76`)**:
   - In both the main text (line 96) and Table 1 (line 102), for the extreme RPD WGS cohort (`AMD+/RPD++`, $N = 44$, genotype counts `GG/GA/AA = 7/22/15`, risk allele `A` frequency $= 52/88 = 0.591 \approx 0.60$) compared to `AMD-/RPD-` controls ($N = 1,008$, `GG/GA/AA = 568/374/66`, risk allele `A` frequency $= 506/2016 = 0.251$), the authors report: **`OR = 6.54, CI = (11.4–33.76)`** ($P = 2.66 \times 10^{-11}$).
   - A point estimate of `6.54` cannot lie outside its own 95% confidence interval `(11.4–33.76)`! From the raw genotype counts in Table 1, the unadjusted per-allele odds ratio is $\frac{52/36}{506/1510} = 4.31$ (and for homozygous `AA vs. GG`, $\frac{15/7}{66/568} = 18.44$). Evidently, a homozygous genotype OR confidence interval (or a mis-exponentiated bound) was pasted next to the allelic OR point estimate `6.54`.
2. **Misinterpretation of Non-Additive (Dominant vs. Recessive) Model Results (Line 89)**:
   - In the "Non-additive GWAS" section (line 89), the authors find that `rs60401382` at *ARMS2/HTRA1* has $\beta = 0.23$ ($p = 2 \times 10^{-7}$) under a dominant model and $\beta = 0.21$ ($p = 9 \times 10^{-7}$) under a recessive model, whereas the additive model yields $p = 3.4 \times 10^{-11}$, and conclude: *"with the same effect sizes, suggesting the rs60401382 signal is underpinned by a dominant effect."*
   - Statistically, when a true genetic effect is **additive** (linear in allele dosage $0, 1, 2$), fitting a 1-df dominant model ($1, 2 \text{ vs. } 0$) and fitting a 1-df recessive model ($2 \text{ vs. } 0, 1$) both capture a projection of the additive slope and yield similar attenuated $\beta$ values and weaker $p$-values ($10^{-7}$) than the additive model ($10^{-11}$). Equal effect sizes between dominant and recessive models is the expected signature of an **additive** locus, not a dominant one.
3. **Ambiguity of $N = 181$ Zero-Extent Individuals in the `AMD+/RPD+` Extent Analysis (Figure 3)**:
   - The main text (line 81) states that RPD macular extent was quantified "in a subset of AMD+/RPD+ individuals," yet the Figure 3 legend (line 84) states that $N = 181$ of the $N = 526$ individuals (34.4%) "showed a mean extent RPD value of zero" (requiring $\log(x + 0.1)$ transformation). The text should clarify whether $\text{AMD}^+/\text{RPD}^-$ individuals were included in the $N = 526$ sample or whether the AI segmentation assigned zero area to 34.4% of clinician-graded $\text{RPD}^+$ volumes.
4. **Inconsistent Direction of *HTRA1* vs. *HTRA1-AS1* Co-Expression Across Retinal Cohorts**:
   - While the `rs11200638-A` risk allele positively associates with *HTRA1-AS1* and negatively with *HTRA1* mRNA, the authors candidly note (line 122, Supplementary Fig. 16) that direct RNA–RNA correlation between *HTRA1* and *HTRA1-AS1* is positive in the NEI cohort but negative in the Genentech cohort, and no wet-lab perturbation of *HTRA1-AS1* is performed to distinguish causal antisense regulation from shared promoter/enhancer pleiotropy or the linked `ARMS2` `A69S` / `del443ins54` variants.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1**: The chromosome 10q26 *ARMS2/HTRA1/HTRA1-AS1* locus strongly predisposes AMD patients to RPD ($P = 3.73 \times 10^{-15}$) and higher RPD macular extent, whereas the chromosome 1q31 *CFH* locus does not distinguish $\text{AMD}^+/\text{RPD}^+$ from $\text{AMD}^+/\text{RPD}^-$. `[Well Supported]` — Conclusively established by the 14-cohort GWAS meta-analysis and AI-OCT extent analysis.
- **Claim 2**: The 10q26 RPD risk haplotype colocalizes with reduced photoreceptor outer segment (OS) and parafoveal retinal thickness ($\text{PPH4} = 0.99$) and with increased retinal expression of the antisense lncRNA *HTRA1-AS1* ($\text{PPH4} = 0.97$). `[Well Supported]` — Demonstrated via multi-trait Bayesian colocalization and two re-mapped post-mortem retinal eQTL datasets.
- **Claim 3**: `rs60401382` is underpinned by a dominant genetic effect, and `rs11200638` has `OR = 6.54 (95% CI: 11.4–33.76)` in extreme RPD. `[Methodologically Flawed]` — The additive model is superior by 4 orders of magnitude ($p = 3.4 \times 10^{-11}$ vs. $2 \times 10^{-7}$), and the Table 1 CI does not contain its point estimate.

### 4. Reproducibility & Data Completeness
- **Exemplary Open Science & Repository Deposition**: Complete summary statistics are deposited in the GWAS Catalog (`GCST90559231`–`GCST90559242`, including sex-stratified datasets), retinal eQTL datasets are cited by GEO accessions (`GSE115828`, `GSE135092`), pixel-wise UKBB OCT results are on OSF (`10.17605/OSF.IO/KZUGV`), step-by-step protocols are on `protocols.io`, and the deep-learning OCT RPD segmentation model is publicly maintained in the `Project-MONAI` Model Zoo.
</Blinded Review: TIME_ANON_0997>
